Gustave Roussy, Cancer Campus, Grand Paris: clinical-trial pipeline
Gustave Roussy, Cancer Campus, Grand Paris is the sponsor of 243 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 73 are not yet finished and 4 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 78 |
| Not applicable | 66 |
| Phase 3 | 59 |
| Phase 1 | 24 |
| Phase 1/2 | 11 |
| Phase 2/3 | 3 |
| Phase 4 | 2 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 91 |
| Recruiting | 47 |
| Unknown | 44 |
| Terminated | 28 |
| Active, not recruiting | 13 |
| Not yet recruiting | 13 |
| Withdrawn or not authorised | 5 |
| Suspended or halted | 2 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 223 |
| Nephrology and urology | 20 |
| Metabolic and endocrine (diabetes, obesity) | 15 |
| Gastroenterology and liver | 13 |
| Women's health and obstetrics | 12 |
| Musculoskeletal | 6 |
| Dermatology | 5 |
| Haematology | 3 |
| Immunology and rheumatology | 3 |
| Infectious disease and vaccines | 3 |
| Neurology | 3 |
| Psychiatry and mental health | 2 |
Countries
| Country | Trials |
|---|---|
| France | 239 |
| Spain | 15 |
| Italy | 14 |
| Netherlands | 14 |
| United Kingdom | 11 |
| Denmark | 9 |
| Austria | 8 |
| Belgium | 8 |
| Switzerland | 7 |
| Czechia | 6 |
| Poland | 5 |
| Sweden | 5 |
| Australia | 4 |
| Germany | 4 |
| Greece | 4 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-13 | New trial posted | Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Re… |
| 2026-09-09 | New trial posted | Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically… |
| 2026-09-03 | New trial posted | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmaco… |
| 2026-09-03 | New trial posted | Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05631249 | Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | Phase 2 | Active, not recruiting | France |
| NCT04965766 | Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer | Phase 2 | Recruiting | France |
| NCT05476939 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 | Phase 3 | Recruiting | Austria, Belgium, Czechia, Denmark +7 |
| NCT02813135 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory T… | Phase 1/2 | Recruiting | Denmark, Spain, France, United Kingdom +2 |
| NCT04221035 | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | Phase 3 | Recruiting | Austria, Australia, Belgium, Switzerland +19 |
| NCT07082452 | A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Stan… | Phase 3 | Recruiting | Spain, France |
| NCT07808567 | Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreati… | Phase 2 | Not yet recruiting | France |
| NCT03570021 | ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk… | Phase 3 | Active, not recruiting | France, Guadeloupe, Réunion |
| NCT06934057 | Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma | Phase 4 | Recruiting | France |
| NCT05267912 | Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine… | Not applicable | Recruiting | France |
| NCT03351296 | Two Chemotherapy Regimens Plus or Minus Bevacizumab | Phase 2 | Active, not recruiting | France |
| NCT05692999 | Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study | Phase 3 | Recruiting | Belgium, Spain, France |
| NCT06332274 | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease | Phase 3 | Recruiting | France |
| NCT03984318 | Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs | Not applicable | Active, not recruiting | France |
| NCT07471425 | Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine Tumor | Not applicable | Not yet recruiting | France |
| NCT07622017 | KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer | Phase 2 | Not yet recruiting | France |
| NCT06364631 | CARE1 Pragmatic Clinical Trial | Phase 3 | Recruiting | Austria, Czechia, France, Netherlands |
| NCT04842162 | Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection… | Phase 2 | Recruiting | Belgium, France |
| NCT06439888 | Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer | Phase 1/2 | Recruiting | France |
| NCT06781996 | A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life Du… | Phase 3 | Recruiting | France |
| NCT07591493 | Adjuvant Trial in Pancreatic Neuroendocrine Tumors | Phase 3 | Not yet recruiting | France |
| NCT06840782 | First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small C… | Phase 3 | Recruiting | France |
| NCT04932525 | Gustave Roussy Cancer Profiling | Not applicable | Recruiting | France |
| NCT06479057 | PROACT is a Prospective Master Protocol for a Cohort Study Focused on Evaluating the Implementation of Integr… | Not applicable | Recruiting | France |
| NCT03819101 | Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer | Phase 3 | Recruiting | Switzerland, Czechia, France, Italy +2 |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Gustave Roussy, Cancer Campus, Grand Paris clinical trials: 73 open, 62 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/gustave-roussy-cancer-campus-grand-paris/, data as of 2026-10-25.